AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).
"We continue to leverage our Human Response Platform™ in our efforts to maximize the clinical potential of our pipeline of oncology therapeutics," said Murray Robinson, Ph.D., senior vice president, translational medicine at AVEO. "AVEO is committed to advancing the science behind biomarkers and patient treatment approaches. The identification and development of relevant biomarkers is a strategic component of our drug development efforts. We expect to use biomarker data from this study to inform the future design of rational combinations in RCC, as well as in other cancers."
This multi-center, single-arm Phase 2 study is designed to evaluate biomarkers of tivozanib in approximately 100 patients with RCC who had a prior nephrectomy at 25 sites in the U.S. and Canada. A key primary objective of the study is to evaluate biomarkers in blood and archived tissue samples and their correlation with tivozanib clinical activity and/or drug-related toxicity. For more information, please visit www.clinicaltrials.gov.
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery